Canadian Drug Importation How has it been tried before? What are the challenges?



Shabbir Imber Safdar Executive Director The Partnership for Safe Medicines Academy of Managed Care Pharmacy ADAP Advocacy Association Alabama Pharmacy Association Alaska Pharmacists Association American Pharmacists Association Arizona Pharmacy Alliance (AzPA) Association for Accessible Medicines Biotechnology Innovation Organization Colorado BioScience Association Community Access National Network Connecticut Pharmacists Association Delaware Pharmacists Society Healthcare Distribution Association HealthCare Institute of New Jersey HealthHIV

Illinois Pharmacists Association Institute for Safe Medication Practices International AntiCounterfeiting Coalition International Health Facility Diversion Association

Kansas Pharmacists Association

Maine Pharmacy Association Maryland Pharmacists Association Men's Health Network Minnesota Pharmacists Association Mississippi Pharmacy Association Missouri Pharmacy Association National Alliance of State Pharmacy Associations

National Alliance On Mental Illness National Association of Boards of Pharmacy

National Association of Chain Drug Stores Pharmaceutical Security Institute National Association of Drug Diversion RetireSafe Investigators Rx Outreach

National Association of Manufacturers National Coalition for LGBT Health National Consumers League National Grange of the Order of Patrons of Husbandry

Nebraska Pharmacists Association

NeedyMeds

New Hampshire Pharmacists Association New Mexico Pharmacists Association Ohio Pharmacists Association Oklahoma Pharmacists Association Oncology Managers of Florida, Inc. Pennsylvania Pharmacists Association Pharmaceutical Industry Labor-Management Association (PILMA) Pharmaceutical Researchers and Manufacturers of America RetireSafe Rx Outreach **Rx** Partnership Texas Pharmacy Association University of New England College of Pharmacv Virginia Pharmacists Association

The Partnership for SAFEMEDICINES®

Illinois' Experience With ISaveRX, 2003–2006

A "whitelisted" online pharmacy program of 28 online drug sellers dispensing from Canada, the United Kingdom, Australia, and New Zealand to IL, WI, KS, MO, and VT.

Select IG findings:

- Operating in violation of federal law with unapproved federal funds.
- Dispensing entities in the program in violation of IL pharmacy practice law.
- 40% of the inspections records (32 of 80) were not completed.
- State did not monitor that only approved pharmacies participated.
- Significant labor costs of \$488,000 for 26 employees (19 months).
- High expenses, incl. \$111,000 for international travel and over \$350,000 for contract management, marketing, and legal services.
- Uptake of the program was small and it was eventually cancelled.



REPORT DIGEST

MANAGEMENT AUDIT OF THE

FLU VACCINE PROCUREMENT AND THE I-SAVERX PROGRAM

Released: September 2006



State of Illinois Office of the Auditor General

AUDITOR GENERAL

Minnesota RXConnect, 2004-2010

An online pharmacy regulation program started by Gov. Tim Pawlenty. After launch, the FDA cited a number of patient safety issues, including several found during a pre-announced visit by Minnesota's own inspectors:

- Pharmacy techs, not pharmacists, entering prescriptions.
- Having pharmacists check 100 new prescriptions / hour or refill 300 prescriptions / hour.
- Cold-chain drugs shipped not refrigerated / no historic thermometers in refrigerators.
- Allowing pharmacy techs instead of pharmacists contact U.S. medical providers
- Allowing faxed prescriptions.
- Failed to meet minimum lighting standards as set by MN pharmacy law.
- Uptake of the program was small and it was eventually cancelled.



MYTH: "WE ARE GETTING THE SAME DRUGS CANADIANS TAKE."

Testing proves they are not getting the same medicine. They are risking ineffective and dangerous drugs from other countries.

From 2013 until 2015, Maine law allowed the importation of foreign prescription drugs from online "pharmacies" associated with licensed retail pharmacies in Canada, the U.K., Australia and New Zealand, exclusively.

However, the cost savings came with some surprising results.

University of New England Professor Kenneth McCall tested three widely used medications from one of these pharmacy websites. He ordered drugs that are available in brand name and generic in the U.S., and received:

> A non-FDA approved generic of Nexium, esomeprazole (which treats acid reflux disease)

A non-FDA approved generic of Celebrex, **celecoxib** (an anti-inflammatory)

A non-FDA approved generic of Plavix, clopidogrel (a blood thinner)

Maine's program: 2013-2015

Advocates of the Canadian importation promised that the medicines they would receive would come from just over the border in Canada.

The medicines they received from Canadian vendors did not even touch Canadian soil.


The medicines McCall received came from India, Mauritius and Turkey and none of them were approved medicines in the U.S. or Canada. His tests showed: the esomeprazole was only 58% of the stated dose, the celecoxib was only 77% of the stated dose, and the clopidogrel contained an unknown contaminant. Portland's WGME News performed the same experiment with similar results.



INSTEAD OF COMING FROM CANADA'S DRUG SUPPLY, THESE CAME FROM . . .



ON TESTING THEM, HE FOUND:



What happens if patients take black market medicine that is weaker than the stated dose?

Treatment will be ineffective and potentially dangerous. Patients with chronic illnesses such as diabetes and hypertension may get sicker as doses vary between unregulated batches of medicine. Their doctors may presume that treatment is ineffective for that patient instead of realizing that their imported medication is unreliable. When patients take substandard medicines they could suffer serious harm.

To date it is not known how many Mainers were exposed to counterfeit medicines during this time.

©2021 The Partnership for SAFEMEDICINES®

Colorado

Colorado has burned \$3mm in taxpayer money. They don't have a Canadian seller, and they don't have an application into HHS.

They could have saved \$43mm this year if they focused on U.S. generics instead of Canada importation.

Drug	Dose	Colorado Unit Cost (wholesale)	Generic Price	Unit	Generic Unit Cost (retail)		Current CO Price	Money Saved with Generics (retail price)
Advair Diskus	250/50	\$ 4.54	\$ 103.78	60	\$ 1.73	2,844,435	\$ 12,461,754.45	\$ 7,993,810.5
Nuvaring		\$ 154.70	\$ 59.93	1	\$ 59.93	68,578	\$ 10,237,567.86	\$ 6,499,137.0
Advair Diskus	500/50	\$ 5.12	\$ 134.59	60	\$ 2.24	1,455,908	\$ 7,193,348.08	\$ 4,188,404.6
Zytiga	250mg	\$ 86.22	\$ 1,076.3 1	120	\$ 8.97	50,889	\$ 4,234,059.97	\$ 3,931,175.2
Advair Diskus	100/50	\$ 4.67	\$ 84.69	60	\$ 1.41	872,328	\$ 3,931,190.04	\$ 2,842,480.7
Noxafil	100mg	\$ 67.96	\$ 1,789.4 8	90	\$ 19.88	40,697	\$ 2,668,974.67	\$ 1,956,585.3
Gleevec	400mg	\$ 334.84	\$ 193.29	30	\$ 6.44	3,539	\$ 1,143,658.53	\$ 1,162,196.9
Copaxone	20mg	\$ 238.08	\$ 1,181.2 7	30	\$ 39.38	4,703	\$ 1,080,602.09	\$ 934,506.4
Jadenu	360mg	\$ 167.95	\$ 1,628.9 0	60	\$ 27.15	6,525	\$ 1,057,440.17	\$ 918,730.8
Xeloda	500mg	\$ 45.63	\$ 64.93	84	\$ 0.77	17,758	\$ 782,024.14	\$ 796,623.
Portia 28	0.03/0. 15mg	\$ 0.91	\$ 11.26	28	\$ 0.40	1,562,510	\$ 1,364,918.77	\$ 793,531.
Yaz 28	3/0.02 mg	\$ 4.80	\$ 19.32	28	\$ 0.69	175,582	\$ 814,013.37	\$ 721,642.0
Lamictal	100mg	\$ 11.94	\$ 7.62	30	\$ 0.25	61,573	\$ 709,377.23	\$ 719,542.0
Wellbutri n XL	300mg	\$ 14.47	\$ 17.52	30	\$ 0.58	51,109	\$ 713,493.80	\$ 709,699.
Afinitor	5mg	\$ 556.65	\$ 5,095.2 6	28	\$ 181.97	1,443	\$ 775,173.66	\$ 540,658.0
Prograf	1mg	\$ 6.16	\$ 41.65	120	\$ 0.35	84,936	\$ 505,199.29	\$ 493,725.
Synthroid	100mcg	\$ 1.18	\$ 10.00	90	\$ 0.11	404,717	\$ 459,902.57	\$ 432,597.5
Zomig	5mg	\$ 73.99	\$ 8.47	30	\$ 0.28	5,849	\$ 417,576.74	\$ 431,116.

Projected 1 year savings from generics in CO \$43,860,108.09

2021 The Partnership for SAFEMEDICINES®

Maine

We recently FOIA'd documents out of Maine's Medicaid program (MaineCare) showing that they would LOSE MONEY buying medicine from Canada because they wouldn't get rebates.

Medicaid (MaineCare) touches 1 in 5 residents. Many private insurers also get rebates.

					1	D			
Drug Name	Generic or Chemical Name	Condition	A Current: Net unit cost (after rebates and all ether discounts). Please be sure to match price / units	B Drug Utilization (20, FY 2019 utilization)	C Plan Total Net Speed Multiply Column A , plan net price by Column B	Canadian Price* (in USD)	Canadian Price with mark up in USD NASHP-estimated 45% mark up for supply chair profit + costs	Plan Net Spend: Canadian Imports Multiply Canadian price with mark up (E) by utilization from 2Q PT 2015 (8)	Plan Savings from Canadian Importation Subtract F – Plan Net Spend with Canadian price
ABLIFY MAINTENA 300 mg injection pod Otuska Canada	Aripiprazole	Antipscychotic		6		\$342.14" (1 pod)	\$ 496.10	\$ 2,976.62	
ABUFY MAINTENA 400 mg injection pod Otuka Canada	Aripiprazole	Antipscychotic		49		\$342.14° (1 pod)	\$ 496.10	\$ 24,308.69	
ADVAIR DISKUS 100 mcg/50 mcg GlaxoSmithKline	Fluticasone-Salmeterol	Asthma/COPD		442		\$56.84" (60 doses)	\$ 82.42	\$ 36,430.36	
ADVAIR DISKUS 250 mcg/50 mcg GlaxoSmithCline	Fluticasone-Salmeterol	Asthma/COPD		1506		\$68.02" (60 doses)	\$ 98.63	\$ 148,529.81	
ADVAIR DISKUS 500 mcg/50 mcg GlaxoSmithXline	Fluticasone-Salmeterol	Asthma/COPD		585		\$96.56 [°] (60 doses)	\$ \$40.00	\$ 81,902.76	
ATOMOXETINE 30 mg capsule Garanic	Atomosetine HCI	ADHD	5 1.91	7321	\$ 13,568.88	50.38	\$ 0.56	5 4,064.97	\$ 9,903.9
ATOMOXETINE 18 mg capsule Garacic	Atomosetine HCI	ADHD	5 1.44	7705	\$ 11,083.64	\$0.43	\$ 0.63	\$ 4,816.27	\$ 6,267.3
ATOMOXETINE 25 mg capsule Generic	Atomosetine HCI	ADHD	\$ 1.78	13635	\$ 24,268.33	\$0.48	\$ 0.70	\$ 9,519.57	\$ 14,748.7
ATOMOXETINE 40 mg copsule Generic	Atomoxetine HCI	ADHD	\$ 1.34	19373	\$ 25,993.02	\$0.55	\$ 0.80	\$ 15,524.76	\$ 10,468.2
ATOMOXITINE 60 mg copsule Generic	Atomosetine HCI	ADHD	5 1.56	9842	\$ 15,318.34	\$0.61	5 0.88	\$ 8,660.69	\$ 0,057.0
BIKTARVY 50 mg/200 m/25 mg Gilead	Bictegravir-Emtricitabine- Tenofovir AF	HIV		14790		\$29.42	\$ 42.65	5 630,819.38	
BUPROPION HYDROCHLORIDE 100 mg extended release (12 hr) tablet Generic	Bupropion HCI	Smoking Cessation/Antidepressant	\$ 0.06	41309	\$ 2,284.51	\$0.12	\$ 0.17	\$ 6,949.72	\$ (4,665.20
BUPROPION INTEROCHLORIDE 150 mg extended release (12 hr) tablet Generic	Buprepion HCI	Smoking Cestation/Antidepressant	S 0.08	109473	5 8,465.84	\$0.17	5 0.25	\$ 27,346.30	\$ (18,880.44
BUPROPION HYDROCHLORIDE 150 mg extended release (24 hr) tablet Generic	Bupropion HCI	Smoking Cessation/Antidepressant	\$ 0.15	213102	\$ 32,995.08	\$0.11	\$ 0.16	\$ 33,904.85	\$ (909.77
BUPROPION HYDROCHLORIDE 300 mg extended release (24 hr) tablet Generic	Buprepion HCI	Smoking Costation/Antidoprestant	5 0.10	160728	\$ 16,325.30	\$0.22	\$ 0.32	\$ \$1,161.65	5 (34,836.31
EPCLUSA 400 mg/200 mg Gilead	Sofosbuvir-Velpatasvir	Hepatitis C		1834		\$535.71	\$ 776.79	\$ 1,424,624.97	
GABAPENTIN 100 mg capsule Generic	Gabapentin	Nerve Pain	5 0.02	475609	\$ 9,383.84	\$0.03	\$ 0.05	\$ 21,516.55	\$ (12,152.7
GABAPENTIN 300 mg capsule Generic	Gabapentin	Nerve Pain	5 0.04	1930973	\$ 76,174.59	\$0.08	S 0.11	\$ 212,513.26	5 (136,338.68

Projected loss if imported: \$927,983.28

Florida

The Agency for Health Care Administration published a proposed project for \$30mm over 3 years to run their importation program.

Nobody bid.

Hiami Herald

Florida fails to attract bidders for Canada prescription drug importation program PHIL GALEWITZ OCTOBER 23, 2020 01:38 PM

> ²¹ **The Partnership for SAFEMEDICINES**[®]

New Mexico

Six state agencies spent eight months and retained consultant expertise at state expense to develop a Canadian drug importation plan over the objection of Canadians who testified against the plan in February of 2020.

Fifteen days before New Mexico finished their plan, Canada put restrictions on export of medication to the U.S.

Wyoming

"This [limited state control] makes it virtually impossible to guarantee that consumers will actually see savings, particularly in the case of Canadian drug importation. Basic economics also suggests fundamental problems with this plan that make it unsustainable in the long-run."

PRESCRIPTION DRUGS IN WYOMING

Evaluating State policy options for lowering costs



Wyoming Department of Healt October 14, 2020

October 10, 2020 WY Dept. of Health

North Dakota

"The issues of potentially a very limited supply of imported drugs from Canada, and subsequent price equalization both indicate that little if any potential savings could be realized by the State's health program."

Deloitte.

- Date: June 30, 2020
- Fo: Rep. Mike Lefor, Chairman Employee Benefits Programs Committee
- From: Josh Johnson and Dan Plante, Deloitte Consulting LLP

Subject: ACTUARIAL REVIEW OF PROPOSED BILL 21.0068.01000

The following summarizes our review of the proposed legislation as it relates to actuarial impact to the Uniform Group Health Insurance Program administered by NDPERS.

OVERVIEW OF PROPOSED BILL 21.0068.01000

The following is a summary of the relevant proposed amendments

This bill proposes the requirement that prescription drug benefits under the uniform group insurance program must include coverage for prescription drugs imported from Canada (in compliance with section 804 of the Federal Food, Drug, and Cosmetics Act). Coverage required under this section may allow for a copayment that does not exceed \$25.

The bill also would require NDPERS to provide a report to the sixty-eighth Legislative Assembly regarding the effect of the prescription drug coverage requirement on the system's health insurance programs, information on the utilization and costs relating to the coverage, and a recommendation regarding whether the coverage should continue.

ESTIMATED ACTUARIAL IMPACT

There have been numerous reports issued that indicate that the importation of brand (and, ultimately, generic) prescriptions from Canada will not have an impact on US health care prices. Key points from these reports:

- Canada, with a population about 11% that of the US, does not produce sufficient quantities of drugs to allow for meaningful importation into the US without jeopardizing access for Canadians. Any level of a constricting supply for Canadian would likely increase the cost of Canadian drugs given the continued Canadian demand.
- Canada would potentially oppose any importation plan that would either shrink the Canadian drug supply or raise costs for Canadians.

June 30, 2020

²¹ **The Partnership for SAFEMEDICINES**[®]

Has anyone analyzed cost of these programs? Yes.

"While pharmaceutical importation plans are politically attractive, the numbers demonstrate that they fail to deliver cost savings when implemented safely. These schemes can be cheap, or they can be safe, but not both."

State pharmaceutical importation programmes: an analysis of cost effectiveness, Kristina M. L. Acri née Lybecker, Journal of Pharmaceutical Health Services Research, March 18, 2020, Royal Pharmaceutical Society

PHSR Journal of Pharmaceutical Health Services Research

ROYAL PHARMACEUTICAI SOCIETY

State Pharmaceutical Importation Programs: An Analysis of the Cost Effectiveness

Colorado College Working Paper 2019-02 June 2019

58 Pages · Posted: 19 Jun 2019 · Last revised: 26 Jun 2019

Kristina M.L. Acri née Lybecker

Colorado College - Department of Economics & Business

Date Written: June 12, 2019

Abstract

Recently proposed legislation in Colorado, Connecticut, Florida, Maine, Missouri, Oklahoma, Oregon, Utah, Vermont and West Virginia aims to reduce spending on pharmaceuticals by importing them from Canada. To examine the cost effectiveness of importation, this study analyzes 24 drugs from an online Canadian supplier, accounting for the cost savings, the cost of testing, the medical consequences of treatment failure, and the cost of treating an adverse medical event. For a "Representative State", given an adverse medical event, the presumed savings from an online Canadian supplier are exhausted in the treatment of only one patient in the case of Nexium, to 24,318 adverse events for patients in the case of Advair. The analysis shows the cost of testing (99.999% confidence level with 99.999% reliability) exceeds the presumed cost savings in all cases. Pharmaceutical importation plans are politically attractive, but the numbers demonstrate that they fail to deliver cost savings.

Keywords: pharmaceutical importation, drug prices, Canadian pharmacy, cost effectiveness

JEL Classification: F13, F14, H21, H11, H18, L51, L65

Suggested Citation:

D21 The Partnership for SAFEMEDICINES®

History of counterfeits in North Dakota



We struggle to extradite Canadian criminals.

Internet pharmacy pioneer's licence reinstated, just days after it was suspended

Kris Thorkelson's Manitoba licence was pulled on same day his Canada Drugs reached tentative plea deal in U.S.

By Karen Pauls, CBC News Posted: Dec 21, 2017 5:03 PM CT | Last Updated: Dec 21, 2017 5:14 PM CT



American prosecutors accuse CanadaDrugs.com, its CEO Kris Thorkelson, affiliated companies and associates of selling \$78 U.S. in unapproved and counterfeit cancer drugs to U.S. doctors. (CBC) A licensed Canadian wholesaler who admitted to trafficking US\$78mm in counterfeit Avastin to U.S. company beat extradition and was allowed to serve six months house arrest.

We cannot outsource regulation of our medicine supply chain to Canadian entities.

Canada has no track-and-trace system There is no way to track a medicine back to the manufacturing floor if it was made for the Canadian market. There is also no way for the Canadians to do it either.

Shortage issues

Respective population - 2018



🏟 СВС

Breast cancer survivor says Tamoxifen drug shortage is at 'crisis point'

f 🎔 🗖 🥶 in

Pharmacists being asked to limit each patient to 1-month supply of drug, rather than normal 3-month supply



Aly Thomson · CBC News · Posted: Nov 15, 2019 6:00 AM AT | Last Updated: an hour ago



©2021 The Partnership for SAFEMEDICINES®

Canadian action

Canada Blocks Export Of Medications In Short Supply In Response To Trump Plan November 29, 2020

n p r



Canadian Minister of Health Patty Hajdu, pictured in 2016, announced a new rule in response to a U.S. plan to import drugs from Canada. Charly Triballeau/AFP via Getty Images

END OF PRESENTATION

©2021 The Partnership for SAFEMEDICINES®